{"id":2732,"date":"2024-09-04T15:18:00","date_gmt":"2024-09-04T13:18:00","guid":{"rendered":"https:\/\/prueba.esclerosismultiplegalicia.org\/?p=2732"},"modified":"2025-09-05T16:09:09","modified_gmt":"2025-09-05T14:09:09","slug":"sanofi-avanza-no-tratamento-da-esclerose-multiple-progresiva-con-tolebrutinib","status":"publish","type":"post","link":"http:\/\/esclerosismultiplegalicia.org\/index.php\/2024\/09\/04\/sanofi-avanza-no-tratamento-da-esclerose-multiple-progresiva-con-tolebrutinib\/","title":{"rendered":"Sanofi avanza no tratamento da Esclerose M\u00faltiple Progresiva con Tolebrutinib"},"content":{"rendered":"\n<h3 class=\"wp-block-heading has-theme-palette-2-color has-text-color has-link-color wp-elements-ca2f0001776665d81ba3ce927dc49175\"><em>A farmac\u00e9utica francesa logra avances no tratamento da EM Progresiva, a pesares de non acadar todos os obxectivos en formas recorrentes.<\/em><\/h3>\n\n\n\n<p>Sanofi deu un paso na investigaci\u00f3n da Esclerose M\u00faltiple (EM) cos resultados do seu ensaio cl\u00ednico de fase III sobre o f\u00e1rmaco experimental Tolebrutinib. A\u00ednda que o f\u00e1rmaco non cumpriu o seu obxectivo principal no tratamento das formas recorrentes da enfermidade, demostrou ser prometedor nunha variante m\u00e1is dif\u00edcil de tratar.<\/p>\n\n\n\n<h3 class=\"wp-block-heading\">\u00c9xito no tratamento da Esclerose M\u00faltiple Progresiva<\/h3>\n\n\n\n<p>O Tolebrutinib mostrou eficacia no tratamento da EM Progresiva, unha forma menos com\u00fan e m\u00e1is desafiante da enfermidade, caracterizada pola ausencia de brotes definidos e por un empeoramento constante dos s\u00edntomas sen un periodo intermedio de remisi\u00f3n.&nbsp;No ensaio cl\u00ednico, o f\u00e1rmaco logrou ralentizar a progresi\u00f3n da discapacidade en comparaci\u00f3n co placebo, o que representa un avance importante no manexo desta variante da EM.<\/p>\n\n\n\n<p>Houman Ashrafian, director de investigaci\u00f3n e desenvolvemento de Sanofi, resaltou a importancia deste logro: &#8220;O Tolebrutinib representa un avance sen precedentes como posible primeira opci\u00f3n de tratamento da enfermidade cun beneficio clinicamente significativo na acumulaci\u00f3n de discapacidade&#8221;.<\/p>\n\n\n\n<h3 class=\"wp-block-heading\">Perspectivas futuras para o Tolebrutinib<\/h3>\n\n\n\n<p>A pesares de non acadar o seu obxectivo principal nas formas recorrentes da EM, Sanofi segue adiante co seu plan para levar o Tolebrutinib ao mercado. A compa\u00f1\u00eda discutir\u00e1 os seus resultados coas autoridades reguladoras, coa meta de presentar a solicitude de aprobaci\u00f3n para fins de 2024.<\/p>\n\n\n\n<h3 class=\"wp-block-heading\">Sanofi: innovaci\u00f3n m\u00e9dica<\/h3>\n\n\n\n<p>Este avance no tratamento da EM Progresiva s\u00famase a outros logros recentes de Sanofi, como o lanzamento de Beyfortus, un medicamento para protexer aos beb\u00e9s contra unha infecci\u00f3n respiratoria com\u00fan. Estes desenvolvementos forman parte da estratexia do director executivo, Paul Hudson, para fortalecer a confianza dos inversores na carteira de productos farmac\u00e9uticos da compa\u00f1\u00eda.<\/p>\n\n\n\n<p>Tolebrutinib, un produto resultante da adquisici\u00f3n de Principia Biopharma en 2020, pertence a unha clase innovadora de inhibidores da tirosina quinasa (BTK) de Bruton. Estes compostos est\u00e1n dese\u00f1ados para bloquear de maneira selectiva a reacci\u00f3n autoinmune danina responsable da EM, ofrecendo un enfoque m\u00e1is espec\u00edfico que os tratamentos inmunosupresores est\u00e1ndar.<\/p>\n\n\n\n<h3 class=\"wp-block-heading\">Pr\u00f3ximos pasos<\/h3>\n\n\n\n<p>Sanofi presentar\u00e1 os detalles completos dos seus ensaios na pr\u00f3xima conferencia do Comit\u00e9 Europeo para o Tratamento e Investigaci\u00f3n da Esclerose M\u00faltiple (ECTRIMS), que se celebrar\u00e1 o 20 de setembro en Copenhague e online. Ademais, a compa\u00f1\u00eda agarda resultados doutro estudo de fase III, co\u00f1ecido como Perseus, noutra forma progresiva de EM, que se publicar\u00e1n en 2025.<\/p>\n\n\n\n<p>A\u00ednda que o Tolebrutinib non acadou todos os seus obxectivos principais nos ensaios, a s\u00faa eficacia na Esclerose M\u00faltiple Progresiva reforza a posici\u00f3n de Sanofi como un dos l\u00edderes en innovaci\u00f3n en tratamentos para enfermidades autoinmunes.<\/p>\n\n\n\n<p><strong>Podes ler o artigo completo&nbsp;<a href=\"https:\/\/www.plantadoce.com\/empresa\/sanofi-se-queda-a-medias-en-el-desarrollo-de-un-nuevo-farmaco-contra-la-esclerosis-multiple\" target=\"_blank\" rel=\"noreferrer noopener\">aqu\u00ed<\/a>.&nbsp;<\/strong><\/p>\n","protected":false},"excerpt":{"rendered":"<p>A farmac\u00e9utica francesa logra avances no tratamento da EM Progresiva,&hellip; <a class=\"continue\" href=\"http:\/\/esclerosismultiplegalicia.org\/index.php\/2024\/09\/04\/sanofi-avanza-no-tratamento-da-esclerose-multiple-progresiva-con-tolebrutinib\/\">Ler m\u00e1is sobre<span> Sanofi avanza no tratamento da Esclerose M\u00faltiple Progresiva con Tolebrutinib<\/span><\/a><\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_kad_post_transparent":"","_kad_post_title":"","_kad_post_layout":"","_kad_post_sidebar_id":"","_kad_post_content_style":"","_kad_post_vertical_padding":"","_kad_post_feature":"","_kad_post_feature_position":"","_kad_post_header":false,"_kad_post_footer":false,"footnotes":""},"categories":[103],"tags":[102,101],"class_list":["post-2732","post","type-post","status-publish","format-standard","hentry","category-novas","tag-investigacion","tag-tratamentos"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v26.1.1 - https:\/\/yoast.com\/wordpress\/plugins\/seo\/ -->\n<title>Sanofi avanza no tratamento da Esclerose M\u00faltiple Progresiva con Tolebrutinib - FEGADEM<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/esclerosismultiplegalicia.org\/index.php\/2024\/09\/04\/sanofi-avanza-no-tratamento-da-esclerose-multiple-progresiva-con-tolebrutinib\/\" \/>\n<meta property=\"og:locale\" content=\"gl_ES\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Sanofi avanza no tratamento da Esclerose M\u00faltiple Progresiva con Tolebrutinib - FEGADEM\" \/>\n<meta property=\"og:description\" content=\"A farmac\u00e9utica francesa logra avances no tratamento da EM Progresiva,&hellip; Ler m\u00e1is sobre Sanofi avanza no tratamento da Esclerose M\u00faltiple Progresiva con Tolebrutinib\" \/>\n<meta property=\"og:url\" content=\"https:\/\/esclerosismultiplegalicia.org\/index.php\/2024\/09\/04\/sanofi-avanza-no-tratamento-da-esclerose-multiple-progresiva-con-tolebrutinib\/\" \/>\n<meta property=\"og:site_name\" content=\"FEGADEM\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/esclerosemultiplegal?locale=es_ES\" \/>\n<meta property=\"article:published_time\" content=\"2024-09-04T13:18:00+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2025-09-05T14:09:09+00:00\" \/>\n<meta name=\"author\" content=\"admin\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:creator\" content=\"@fegadem\" \/>\n<meta name=\"twitter:site\" content=\"@fegadem\" \/>\n<meta name=\"twitter:label1\" content=\"Escrito por\" \/>\n\t<meta name=\"twitter:data1\" content=\"admin\" \/>\n\t<meta name=\"twitter:label2\" content=\"Tempo de lectura\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutos\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\/\/esclerosismultiplegalicia.org\/index.php\/2024\/09\/04\/sanofi-avanza-no-tratamento-da-esclerose-multiple-progresiva-con-tolebrutinib\/#article\",\"isPartOf\":{\"@id\":\"https:\/\/esclerosismultiplegalicia.org\/index.php\/2024\/09\/04\/sanofi-avanza-no-tratamento-da-esclerose-multiple-progresiva-con-tolebrutinib\/\"},\"author\":{\"name\":\"admin\",\"@id\":\"https:\/\/esclerosismultiplegalicia.org\/#\/schema\/person\/6c5800f07aa0462086b750a2df88cfb4\"},\"headline\":\"Sanofi avanza no tratamento da Esclerose M\u00faltiple Progresiva con Tolebrutinib\",\"datePublished\":\"2024-09-04T13:18:00+00:00\",\"dateModified\":\"2025-09-05T14:09:09+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\/\/esclerosismultiplegalicia.org\/index.php\/2024\/09\/04\/sanofi-avanza-no-tratamento-da-esclerose-multiple-progresiva-con-tolebrutinib\/\"},\"wordCount\":500,\"publisher\":{\"@id\":\"https:\/\/esclerosismultiplegalicia.org\/#organization\"},\"keywords\":[\"Investigaci\u00f3n\",\"Tratamentos\"],\"articleSection\":[\"Novas\"],\"inLanguage\":\"gl-ES\"},{\"@type\":\"WebPage\",\"@id\":\"https:\/\/esclerosismultiplegalicia.org\/index.php\/2024\/09\/04\/sanofi-avanza-no-tratamento-da-esclerose-multiple-progresiva-con-tolebrutinib\/\",\"url\":\"https:\/\/esclerosismultiplegalicia.org\/index.php\/2024\/09\/04\/sanofi-avanza-no-tratamento-da-esclerose-multiple-progresiva-con-tolebrutinib\/\",\"name\":\"Sanofi avanza no tratamento da Esclerose M\u00faltiple Progresiva con Tolebrutinib - FEGADEM\",\"isPartOf\":{\"@id\":\"https:\/\/esclerosismultiplegalicia.org\/#website\"},\"datePublished\":\"2024-09-04T13:18:00+00:00\",\"dateModified\":\"2025-09-05T14:09:09+00:00\",\"breadcrumb\":{\"@id\":\"https:\/\/esclerosismultiplegalicia.org\/index.php\/2024\/09\/04\/sanofi-avanza-no-tratamento-da-esclerose-multiple-progresiva-con-tolebrutinib\/#breadcrumb\"},\"inLanguage\":\"gl-ES\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/esclerosismultiplegalicia.org\/index.php\/2024\/09\/04\/sanofi-avanza-no-tratamento-da-esclerose-multiple-progresiva-con-tolebrutinib\/\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/esclerosismultiplegalicia.org\/index.php\/2024\/09\/04\/sanofi-avanza-no-tratamento-da-esclerose-multiple-progresiva-con-tolebrutinib\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Inicio\",\"item\":\"https:\/\/esclerosismultiplegalicia.org\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Sanofi avanza no tratamento da Esclerose M\u00faltiple Progresiva con Tolebrutinib\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/esclerosismultiplegalicia.org\/#website\",\"url\":\"https:\/\/esclerosismultiplegalicia.org\/\",\"name\":\"FEGADEM\",\"description\":\"Traballamos mellorando a calidade de vida das persoas con Esclerose M\u00faltiple en Galicia.\",\"publisher\":{\"@id\":\"https:\/\/esclerosismultiplegalicia.org\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/esclerosismultiplegalicia.org\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"gl-ES\"},{\"@type\":\"Organization\",\"@id\":\"https:\/\/esclerosismultiplegalicia.org\/#organization\",\"name\":\"FEGADEM (Federaci\u00f3n Galega de Esclerose M\u00faltiple)\",\"url\":\"https:\/\/esclerosismultiplegalicia.org\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"gl-ES\",\"@id\":\"https:\/\/esclerosismultiplegalicia.org\/#\/schema\/logo\/image\/\",\"url\":\"http:\/\/esclerosismultiplegalicia.org\/wp-content\/uploads\/2025\/05\/cropped-FEGADEM_Imagotipo-scaled-1.png\",\"contentUrl\":\"http:\/\/esclerosismultiplegalicia.org\/wp-content\/uploads\/2025\/05\/cropped-FEGADEM_Imagotipo-scaled-1.png\",\"width\":2558,\"height\":1138,\"caption\":\"FEGADEM (Federaci\u00f3n Galega de Esclerose M\u00faltiple)\"},\"image\":{\"@id\":\"https:\/\/esclerosismultiplegalicia.org\/#\/schema\/logo\/image\/\"},\"sameAs\":[\"https:\/\/www.facebook.com\/esclerosemultiplegal?locale=es_ES\",\"https:\/\/x.com\/fegadem\",\"https:\/\/www.instagram.com\/esclerosemultiplegal\/\",\"https:\/\/www.youtube.com\/@fegademfederaciongalegadee3374\"]},{\"@type\":\"Person\",\"@id\":\"https:\/\/esclerosismultiplegalicia.org\/#\/schema\/person\/6c5800f07aa0462086b750a2df88cfb4\",\"name\":\"admin\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"gl-ES\",\"@id\":\"https:\/\/esclerosismultiplegalicia.org\/#\/schema\/person\/image\/\",\"url\":\"https:\/\/secure.gravatar.com\/avatar\/6b01f9a90ea05bdd1053be7f0879b99bae6103fa66164176a65e4bd6fee73fba?s=96&d=mm&r=g\",\"contentUrl\":\"https:\/\/secure.gravatar.com\/avatar\/6b01f9a90ea05bdd1053be7f0879b99bae6103fa66164176a65e4bd6fee73fba?s=96&d=mm&r=g\",\"caption\":\"admin\"},\"sameAs\":[\"https:\/\/prueba.esclerosismultiplegalicia.org\"],\"url\":\"http:\/\/esclerosismultiplegalicia.org\/index.php\/author\/admin\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Sanofi avanza no tratamento da Esclerose M\u00faltiple Progresiva con Tolebrutinib - FEGADEM","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/esclerosismultiplegalicia.org\/index.php\/2024\/09\/04\/sanofi-avanza-no-tratamento-da-esclerose-multiple-progresiva-con-tolebrutinib\/","og_locale":"gl_ES","og_type":"article","og_title":"Sanofi avanza no tratamento da Esclerose M\u00faltiple Progresiva con Tolebrutinib - FEGADEM","og_description":"A farmac\u00e9utica francesa logra avances no tratamento da EM Progresiva,&hellip; Ler m\u00e1is sobre Sanofi avanza no tratamento da Esclerose M\u00faltiple Progresiva con Tolebrutinib","og_url":"https:\/\/esclerosismultiplegalicia.org\/index.php\/2024\/09\/04\/sanofi-avanza-no-tratamento-da-esclerose-multiple-progresiva-con-tolebrutinib\/","og_site_name":"FEGADEM","article_publisher":"https:\/\/www.facebook.com\/esclerosemultiplegal?locale=es_ES","article_published_time":"2024-09-04T13:18:00+00:00","article_modified_time":"2025-09-05T14:09:09+00:00","author":"admin","twitter_card":"summary_large_image","twitter_creator":"@fegadem","twitter_site":"@fegadem","twitter_misc":{"Escrito por":"admin","Tempo de lectura":"2 minutos"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/esclerosismultiplegalicia.org\/index.php\/2024\/09\/04\/sanofi-avanza-no-tratamento-da-esclerose-multiple-progresiva-con-tolebrutinib\/#article","isPartOf":{"@id":"https:\/\/esclerosismultiplegalicia.org\/index.php\/2024\/09\/04\/sanofi-avanza-no-tratamento-da-esclerose-multiple-progresiva-con-tolebrutinib\/"},"author":{"name":"admin","@id":"https:\/\/esclerosismultiplegalicia.org\/#\/schema\/person\/6c5800f07aa0462086b750a2df88cfb4"},"headline":"Sanofi avanza no tratamento da Esclerose M\u00faltiple Progresiva con Tolebrutinib","datePublished":"2024-09-04T13:18:00+00:00","dateModified":"2025-09-05T14:09:09+00:00","mainEntityOfPage":{"@id":"https:\/\/esclerosismultiplegalicia.org\/index.php\/2024\/09\/04\/sanofi-avanza-no-tratamento-da-esclerose-multiple-progresiva-con-tolebrutinib\/"},"wordCount":500,"publisher":{"@id":"https:\/\/esclerosismultiplegalicia.org\/#organization"},"keywords":["Investigaci\u00f3n","Tratamentos"],"articleSection":["Novas"],"inLanguage":"gl-ES"},{"@type":"WebPage","@id":"https:\/\/esclerosismultiplegalicia.org\/index.php\/2024\/09\/04\/sanofi-avanza-no-tratamento-da-esclerose-multiple-progresiva-con-tolebrutinib\/","url":"https:\/\/esclerosismultiplegalicia.org\/index.php\/2024\/09\/04\/sanofi-avanza-no-tratamento-da-esclerose-multiple-progresiva-con-tolebrutinib\/","name":"Sanofi avanza no tratamento da Esclerose M\u00faltiple Progresiva con Tolebrutinib - FEGADEM","isPartOf":{"@id":"https:\/\/esclerosismultiplegalicia.org\/#website"},"datePublished":"2024-09-04T13:18:00+00:00","dateModified":"2025-09-05T14:09:09+00:00","breadcrumb":{"@id":"https:\/\/esclerosismultiplegalicia.org\/index.php\/2024\/09\/04\/sanofi-avanza-no-tratamento-da-esclerose-multiple-progresiva-con-tolebrutinib\/#breadcrumb"},"inLanguage":"gl-ES","potentialAction":[{"@type":"ReadAction","target":["https:\/\/esclerosismultiplegalicia.org\/index.php\/2024\/09\/04\/sanofi-avanza-no-tratamento-da-esclerose-multiple-progresiva-con-tolebrutinib\/"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/esclerosismultiplegalicia.org\/index.php\/2024\/09\/04\/sanofi-avanza-no-tratamento-da-esclerose-multiple-progresiva-con-tolebrutinib\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Inicio","item":"https:\/\/esclerosismultiplegalicia.org\/"},{"@type":"ListItem","position":2,"name":"Sanofi avanza no tratamento da Esclerose M\u00faltiple Progresiva con Tolebrutinib"}]},{"@type":"WebSite","@id":"https:\/\/esclerosismultiplegalicia.org\/#website","url":"https:\/\/esclerosismultiplegalicia.org\/","name":"FEGADEM","description":"Traballamos mellorando a calidade de vida das persoas con Esclerose M\u00faltiple en Galicia.","publisher":{"@id":"https:\/\/esclerosismultiplegalicia.org\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/esclerosismultiplegalicia.org\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"gl-ES"},{"@type":"Organization","@id":"https:\/\/esclerosismultiplegalicia.org\/#organization","name":"FEGADEM (Federaci\u00f3n Galega de Esclerose M\u00faltiple)","url":"https:\/\/esclerosismultiplegalicia.org\/","logo":{"@type":"ImageObject","inLanguage":"gl-ES","@id":"https:\/\/esclerosismultiplegalicia.org\/#\/schema\/logo\/image\/","url":"http:\/\/esclerosismultiplegalicia.org\/wp-content\/uploads\/2025\/05\/cropped-FEGADEM_Imagotipo-scaled-1.png","contentUrl":"http:\/\/esclerosismultiplegalicia.org\/wp-content\/uploads\/2025\/05\/cropped-FEGADEM_Imagotipo-scaled-1.png","width":2558,"height":1138,"caption":"FEGADEM (Federaci\u00f3n Galega de Esclerose M\u00faltiple)"},"image":{"@id":"https:\/\/esclerosismultiplegalicia.org\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/esclerosemultiplegal?locale=es_ES","https:\/\/x.com\/fegadem","https:\/\/www.instagram.com\/esclerosemultiplegal\/","https:\/\/www.youtube.com\/@fegademfederaciongalegadee3374"]},{"@type":"Person","@id":"https:\/\/esclerosismultiplegalicia.org\/#\/schema\/person\/6c5800f07aa0462086b750a2df88cfb4","name":"admin","image":{"@type":"ImageObject","inLanguage":"gl-ES","@id":"https:\/\/esclerosismultiplegalicia.org\/#\/schema\/person\/image\/","url":"https:\/\/secure.gravatar.com\/avatar\/6b01f9a90ea05bdd1053be7f0879b99bae6103fa66164176a65e4bd6fee73fba?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/6b01f9a90ea05bdd1053be7f0879b99bae6103fa66164176a65e4bd6fee73fba?s=96&d=mm&r=g","caption":"admin"},"sameAs":["https:\/\/prueba.esclerosismultiplegalicia.org"],"url":"http:\/\/esclerosismultiplegalicia.org\/index.php\/author\/admin\/"}]}},"_links":{"self":[{"href":"http:\/\/esclerosismultiplegalicia.org\/index.php\/wp-json\/wp\/v2\/posts\/2732","targetHints":{"allow":["GET"]}}],"collection":[{"href":"http:\/\/esclerosismultiplegalicia.org\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"http:\/\/esclerosismultiplegalicia.org\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"http:\/\/esclerosismultiplegalicia.org\/index.php\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"http:\/\/esclerosismultiplegalicia.org\/index.php\/wp-json\/wp\/v2\/comments?post=2732"}],"version-history":[{"count":1,"href":"http:\/\/esclerosismultiplegalicia.org\/index.php\/wp-json\/wp\/v2\/posts\/2732\/revisions"}],"predecessor-version":[{"id":2733,"href":"http:\/\/esclerosismultiplegalicia.org\/index.php\/wp-json\/wp\/v2\/posts\/2732\/revisions\/2733"}],"wp:attachment":[{"href":"http:\/\/esclerosismultiplegalicia.org\/index.php\/wp-json\/wp\/v2\/media?parent=2732"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"http:\/\/esclerosismultiplegalicia.org\/index.php\/wp-json\/wp\/v2\/categories?post=2732"},{"taxonomy":"post_tag","embeddable":true,"href":"http:\/\/esclerosismultiplegalicia.org\/index.php\/wp-json\/wp\/v2\/tags?post=2732"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}